Add Axios as your preferred source to

see more of our stories on Google.

Illustration: Aïda Amer/Axios. Stock: Getty Images

Artificial intelligence is dramatically speeding up drug development — and a proprietary survey shows how it's priming a bigger automation push that's changing the trajectory of early stage pharma research.

Why it matters: The TD Cowen survey of 80 biopharma leaders and insiders finds AI is compressing drug developers' preclinical costs and timelines by as much as 70%.